2023 Fiscal Year Final Research Report

Utility of a fully automated urine particle analyzer in monitoring antibiotic therapy for severe urinary tract infections

Research Project

PDF

Project/Area Number	21K09413
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Review Section	Basic Section 56030:Urology-related
Research Institution	Hyogo Medical University
Principal Investigator	Yamamoto Shingo 兵庫医科大学, 医学部, 教授 (80322741)
Co-Investigator(Kenkyū-buntansha)	山崎栄樹帯広畜産大学, 動物・食品検査診断センター, 准教授 (40514708) 奥村香世国立感染症研究所, 安全実験管理部, 主任研究官 (70415561) 兼松明弘兵庫医科大学, 医学部, 教授 (90437202)
Project Period (FY)	2021-04-01 – 2024-03-31
Keywords	尿路感染症 / 薬剤感受性試験 / UF-5000
Outline of Final Research Achievements	The UF-5000 can obtain highly accurate urinary bacterial information using flow cytometry, and by capturing changes in bacterial morphology caused by antibiotics. The purpose of this study was to determine the effectiveness of administered antibiotics early after the start of treatment. First, in an experimental pure culture system, when the causative bacteria are susceptible to antibiotics, changes in bacterial morphology (filamentation, etc.) due to bacteriolysis and a decrease in the number of bacteria were observed within 24 hours after the start of antibiotic treatment (after administration). Similar findings have been observed in clinical practice. UF-5000 detected the decrease in the number of bacteria and the change in bacterial morphology immediately after the initial administration of antibiotics, suggesting that It would be possible to judge the therapeutic effect of the administered antibiotic without waiting for drug susceptibility test results using urine culture.
Free Research Field	尿路感染症
Academic Significance and Societal Importance of the Research Achievements	本研究では、抗菌薬治療中の患者尿検体をUF-5000で測定することによって、通常の薬剤感受性試験では3～4日を必要とするエンピリックセラピーの有効性判定が、より早期に判定できる可能性があることを示した。尿培養よる薬剤感受性試験よりも迅速な抗菌薬の有効性判定方法が確立されれば、耐性菌などで抗菌薬の効果が不十分であった場合など早期に発見することも可能である。患者にとってより安全で効率的な治療を提供することができ、抗菌薬投与期間の短縮、入院治療日数の短縮、耐性菌誘導の回避などが可能になることから、医療経済にも大きく貢献できる。